Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3459876 | 0.95 | ALDH1A1 (0.44) | ALDH1A1RAPGEF4L3MBTL1HDAC4 | |
| Hydrochloric Acid SCHEMBL22366757 | 0.93 | ALDH1A1 (0.42) | ALDH1A1RAPGEF4L3MBTL1HDAC4 | |
| Hydrochloric Acid SCHEMBL29399312 | 0.93 | ALDH1A1 (0.42) | ALDH1A1RAPGEF4L3MBTL1HDAC4 | |
| SCHEMBL3670715 | 0.82 | CYP3A4 (0.43) | ALDH1A1L3MBTL1 | |
| SCHEMBL67360 | 0.76 | RAPGEF4 (0.42) | ALDH1A1RAPGEF4HDAC4 | |
| SCHEMBL12950434 | 0.75 | KDM4E (0.45) | ALDH1A1 | |
| SCHEMBL1548545 | 0.75 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL19142238 | 0.75 | CYP3A4 (0.38) | ALDH1A1RAPGEF4 | |
| SCHEMBL560909 | 0.71 | CYP3A4 (0.35) | ALDH1A1 | |
| SCHEMBL22587947 | 0.71 | ALDH1A1 (0.43) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3958865-B1 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES | BAYER AG (DE) | 2025-12-10 | — | — | EP | disclosed |
| US-12403135-B2 | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2025-09-02 | — | — | US | disclosed |
| EP-3700904-B1 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES | BAYER AG (DE) | 2023-07-19 | — | — | EP | disclosed |
| US-20220378762-A1 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-12-01 | — | — | US | disclosed |
| US-11339157-B1 | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-24 | — | — | US | disclosed |
| WO-2020216774-A1 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-10-29 | — | — | WO | disclosed |
| EP-3700904-A1 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES | Bayer AG (DE) | 2020-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220378762-A1 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES | EGFR, ERBB2, ERBB4 | ALDH1A1 1255/4885RAPGEF4 4209/4885L3MBTL1 889/4885 |
| US-12403135-B2 | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives | EGFR, ERBB2, ERBB4 | ALDH1A1 1255/4885RAPGEF4 4209/4885L3MBTL1 889/4885 |
| US-11339157-B1 | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives | CYP4B1, CYP2C19, CYP3A4 | ALDH1A1 387/4885RAPGEF4 2013/4885L3MBTL1 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.